Search

The study aimed to identify Trichoderma harzianum isolates morphologically and by using PCR teqnique and evaluate the antifungal activity of T. harzianum CA-07 crude extract against Trichophyton mentagrophytes and Microsporium canis from patients with dermatophytosis. T.harzianum isolates were collected from the soil of Baghdad University gardens and they were identified depending of morphological features on plate and microscopic examination. The genomic DNA of T.harzianum isolate was extracted at a final concentration of (400-600) μg / 2-3 g of wet mycelium and at a purity of 1.6-1.8and DNA sample was amplified with each of universal primers (ITS-1& ITS-4) to be used for detection of Trichoderma species. The crude extract was extracted from T.harzianum strain CA-07 by ethyl acetate with finalyield of 4.8gm., then different crude extract concentrations (0.5, 1, 2 and 4 mg/ml) were used against the clinical pathogenic fungi (T.mentagrophyte and M.canis) using agar well diffusion method. The results of identification of Trichoderma harzianum isolates by using PCR confirmed that the isolate was T.harzianum strain CA-07,and their crude extract exhibited significantly high antifungal activity against T. mentagrophyte and M. canis with high growth inhibition zones(14, 12mm) respectively at the lower concentration (0.5mg/ml)of crude extract. [ABSTRACT FROM AUTHOR]

Background: Shortening the process of prescribing via permitting the pharmacist to select the most appropriate pharmaceuticals for each particular patient may provide great opportunities for pharmacists to develop suitable pharmaceutical care plan, monitor and follow up prescribed medications, communicate and consult physicians for more confirmations., Objective: The objective of the current protocol for the systematic review and meta-analysis of pharmacists prescribing interventions was to explore, investigate the evidence, assess and compare PICO in patients with medical conditions (population), receiving pharmacist's prescribing care services (interventions) versus non-pharmacist's prescribing (comparators), and identify how it will impact the clinical, humanistic, and economic patient's outcomes (outcomes)., Methods: The necessary elements of PRISMA will be strictly followed to report the systematic review. The meta-analysis will be reported in line with the Cochrane guidelines for synthesis of trials and all forms will be based on quality measures as per the validated Cochrane templates. We will present the results of the systematic review and the meta-analysis based on PICO comparison between the included trials., Results: We have identified four models of pharmacist prescribing interventions (independent, dependent [collaborative], supplementary, and emergency prescribing). The results will contain a systematic critical evaluation of the included trials in terms of the sample number of the population (characteristics), the type of interventions and the comparators, and the main outcome measures., Conclusion: This protocol will report the evidence and explore the magnitude of impact of pharmacist prescribing interventions, on clinical, humanistic, and economic outcomes. ., (Copyright: © Pharmacy Practice.)